Europe Pharmaceutical Blister Packaging Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Pharmaceutical blister packaging involves sealing solid oral dosage forms, tablets and capsules, between a cavity-formed plastic or film base and a heat-sealable lidding foil, predominantly aluminum. Over half of all global medicines are administered as solid oral doses, the majority of which are packaged in blister configurations within Europe. The European segment commands a significant share of the global market, with Germany representing the largest national pharmaceutical market on the continent.

• •Germany represents Europe's largest pharmaceutical market, consuming billions of medication units annually
• •No official statistical agency tracks blister packaging as an isolated market segment; data relies on industry research groups
• •Aluminum blister configurations dominate the European pharmaceutical supply chain

The broader European pharmaceutical sector forms the primary engine for blister packaging demand, with the global pharmaceutical industry forecast to reach $2.35 trillion by 2030 at a 6.12% CAGR. Aging populations, rising chronic disease prevalence, and expanding generic drug markets across Europe sustain consistent demand for unit-dose blister formats. Regulatory pressure from evolving EU packaging directives is also reshaping product development priorities toward recyclable materials.

• •Rising prevalence of chronic diseases and aging demographics across Europe increase solid oral dosage consumption
• •EU packaging regulations are mandating a structural shift toward recyclable blister configurations
• •The global pharmaceutical sector's projected growth to $2.35 trillion by 2030 underpins packaging demand

PVC composite pharmaceutical blisters constitute a substantial portion of the European PVC market, with approximately 5.4 million tonnes produced annually across the continent. Germany anchors regional demand, followed by France, the United Kingdom, and Italy as key consumption markets. The broader European pharmaceutical packaging and labeling segment is projected to reach $35.78 billion by 2028, with blister formats representing the dominant sub-segment within that figure.

• •Germany is the continent's largest pharmaceutical market, driving the bulk of European blister demand
• •Composite pharmaceutical blisters form a significant portion of the 5.4 million tonnes of annual European PVC production
• •The overall European pharmaceutical packaging and labeling market is projected to reach $35.78 billion by 2028

What are the recent trends and outlook?

Sustainability is the defining strategic theme, with European market dynamics rapidly shifting toward recyclable blister configurations in response to EU regulatory frameworks. Industry and academic researchers are actively developing dissolution-based recycling methods to recover pure PVC from composite pharmaceutical packaging. Paper-based blister alternatives and reduced-waste design approaches are gaining research traction, though aluminum-lidded formats remain dominant due to barrier performance requirements. The market is expected to maintain its 6.0% CAGR through the forecast period, supported by continued pharmaceutical sector expansion and regulatory-driven packaging innovation.

• •EU packaging regulations up to 2025 are driving a structural shift toward recyclable blister configurations
• •Researchers are developing dissolution-based recycling methods to recover pure PVC from composite pharmaceutical blisters
• •Paper-based blister alternatives and waste-reduction strategies are emerging as key innovation areas